How Celox Blood Clotting Agents Work

Celox™ blood clotting granules are actually very high surface area flakes. When they come in contact with blood, Celox™ swells, gels, and sticks together to make a gel like clot, without generating any heat. Celox™ blood clotting agents do not set off the normal clotting cascade, it only clots the blood it comes directly into contact with.

This mode of action has a number of major benefits:

  • Quickly clots hypothermic blood.
  • Works on blood thinners.
  • Works on blood with anti-platelet drugs.
  • No heat generated.
  • Leftover material is naturally absorbed by the body.

Celox quickly clots hypothermic (cold) blood

Blood Clotting Agents Clot speed in hypothermic bloodSevere traumatic blood loss quickly leads to the victim becoming hypothermic, irrespective of the outside temperature. Hypothermic blood is coagulopathic (does not clot normally) and so becomes harder to stop.  

Because of the way Celox works, it is just as effective in stopping bleeding in hypothermic blood as it is in normal temperature blood and independent testing3 confirms this.

Blood thinners (anticoagulants) and anti-platelet therapy

Celox Granules works on casualties using blood thinners (anticoagulants) and anti-platelet therapy.

An increasing number of people are on anticoagulants, presenting an extra challenge if they are injured. With Celox, this is not a concern as it works equally well on blood containing anti-coagulants and this has been tested on blood containing heparin or warfarin1,2,3.

In fact Celox works in a range of difficult bleeding problems, as shown in published results using Celox in patients with severe coagulation problems4. These are cases of bleeding after complex surgery where other hemostatic agents had failed to control the problem.

“Celox simply clots the blood once it comes directly into contact with it, thus not setting off the normal clotting cascade. Since chitosan works independently from the physiological clotting mechanisms, it has also been proved to work in the presence of common anti-coagulants such as warfarin as well as in the presence of heparin

Ref. 4.

Proven safe and no heat generated

Celox™ blood clotting agents are made with chitosan, a natural polysaccharide. Chitosan has a known metabolic pathway. That means any residues left in the body is broken down by the body’s normal enzymes and converted into materials normally present in the body. This is unlike other haemostats that can leave mineral residuals in the body6,7.

Chitosan is digested by lysozyme, a human enzyme which is present is tears, saliva and mucus. When digested by lysozyme Chitosan is broken down into glucosamine a sugar already present in the body. Glucosamine can help lubricate joints8.

Celox Blood Clotting FlakesThe chitosan in Celox is a specific high quality grade selected for medical use from a shellfish source and the product has been through extensive safety testing to the most stringent class of European Medical Device regulations. As part of this work the chitosan has been tested on human subjects with confirmed fish or shrimp hypersensitivity and none of the subjects showed any skin reaction to the chitosan5.

No Heat

Celox blood clotting agents do not produce any heat at all in use, unlike some mineral-based hemostats.

  1. Laboratory assessment of a new hemostat able to clot blood containing anticoagulant. Johnson L et al. SAWC, April 2008, San Diego
  2. Chitosan arrests bleeding in major hepatic injuries with clotting dysfunction: an in vivo experimental study in a model of hepatic injury in the presence of moderate systemic heparinisation. Millner R, Lockhart AS, Marr R. Ann R Coll Surg Engl 2010: 92. [pdf]
  3. Hemostatic effect of a chitosan linear polymer (Celox) in a severe femoral artery bleeding rat model under hypothermia or warfarin therepy. Koksal O et al. Turk J Trauma & Emerg Surg. 2011; 17 (3):199-204.
  4. accessed 13 July 2012.
  5. Medtrade data on file.
  6. Moeng SF, Moar JJ. Quikclot masquerading as Glazer shot: a new forensic pathology artefact? Am J Forensic Med Pathol 2012; 33(3): 238-241.
  7. Hoggarth A, Alden M. Evaluation of the use of hemostatic agents and the residual particles left in the wound. Presented at Symposium for Advanced Wound Care, Anaheim, 2010
  8. Int. J. Biol. Macromol., 1992, Vol 14 August

The Clear Advantage

Success Stories

Leg Injury

While on patrol an Afghan National Army soldier was injured as a result of an IED blast. He sustained a below knee traumatic amputation of the…

Read More

For Further Info & Sales

Contact us or
Click here for enquiry